
NCTN Adolescent and Young Adult (AYA) Cancer Trials Portfolio (Updated on 11/15/2025)

Click on trial number to go to the associated ClinicalTrials.gov webpage, to view the protocol title and the study information.



NCTN Adolescent and Young Adult (AYA) Cancer Trials (Open as of 11/15/2025)

Protocol Number	Phase	Protocol Title
		A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to
A041501	III	Frontline Therapy in Young Adults (Ages 18-39 Years) with Newly Diagnosed Precursor B-Cell ALL
		A Phase II Study of Cabozantinib in Combination with Cemiplimab (REGN2810) (Cabo-Cemiplimab (REGN-2810)) Versus Cabozantinib
A092204	II	Alone in Adolescents and Adults with Advanced Adrenocortical Cancer
		A Phase 2 Study of Blinatumomab (NSC# 765986) in Combination with Nivolumab (NSC # 748726), a Checkpoint Inhibitor of PD-1, in B-
AALL1821	II	ALL Patients Aged >/= 1 to < 31 Years Old with First Relapse
		Randomized Phase 2/3 Trial of Vincristine-Irinotecan-Regorafenib in Combination with Vincristine-Doxorubicin-Cyclophosphamide (VDC)
AEWS2431	11/111	and Ifosfamide-Etoposide (IE) in Patients with Newly Diagnosed Metastatic Ewing Sarcoma
		A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and
AGCT1531	Ш	Adult Patients with Germ Cell Tumors
		A Randomized Phase 3 Trial of Accelerated Versus Standard BEP Chemotherapy for Patients with Intermediate and Poor-Risk Germ Cell
AGCT1532	Ш	Tumors
		A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy with Immuno-oncology Therapy for Children and
AHOD2131	Ш	Adults with Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma
		A Phase 3 Randomized Controlled Trial Comparing Open vs Thoracoscopic Management of Pulmonary Metastases in Patients with
AOST2031	Ш	Osteosarcoma
		A Feasibility and Randomized Phase 2/3 Study of the VEFGR2/MET Inhibitor Cabozantinib in Combination with Cytotoxic Chemotherapy
AOST2032	11/111	for Newly Diagnosed Osteosarcoma
		A Phase II Study of Daratumumab-Hyaluronidase for Chemotherapy-Relapsed/Refractory Minimal Residual Disease (MRD) in T Cell
EA9213	II	Acute Lymphoblastic Leukemia/Lymphoma (T-ALL/T-LBL)
		A Phase III Adjuvant Trial Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in
NRG-BR009	III	Premenopausal Patients with pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score = 25 (OFSET)</td
		A Phase I/II Study of AKR1C3-Activated Prodrug OBI-3424 (OBI-3424) In Patients with Relapsed/Refractory T-Cell Acute Lymphoblastic
S1905	1/11	Leukemia (T-ALL)/T-Cell Lymphoblastic Lymphoma (T-LBL)